RemovedRisk Factors
In addition, Congress enacted other statutes that could adversely affect our ability to successfully commercialize our products. The American Rescue Plan Act of 2021 eliminated the statutory cap on Medicaid Drug Rebate program rebates that manufacturers pay to state Medicaid programs, effective January 1, 2024. Previously, the rebate was capped at the drug’s average manufacturer price. Removal of the rebate cap could increase our Medicaid rebate liability.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions, or incur other harm to our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may not be able to generate sufficient cash to service or repay our indebtedness, which may have a material adverse effect on our financial position, results of operations, and cash flows.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may borrow up to $2.0 billion under our Credit Agreement, which matures in March 2029. Currently, our outstanding principal balance is $300.0 million. Our ability to repay or refinance our debt obligations under our Credit Agreement and any future debt that we may incur will depend on our financial condition and operating performance, which are subject to factors beyond our control. We may be unable to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal and interest on our indebtedness. Our inability to generate sufficient cash flows to satisfy our debt obligations would materially and adversely affect our financial position and results of operations. If we cannot repay or refinance our debt as it becomes due, we may be forced to take disadvantageous actions, including reducing or delaying investments and capital expenditures, disposing of material assets or operations, seeking additional debt or equity capital, or restructuring or refinancing our indebtedness. We may not be able to implement any such alternative measures on commercially reasonable terms or at all and, even if successful, such actions may not enable us to meet any such debt service obligations. In addition, our ability to withstand competitive pressures and to react to changes in our industry could be impaired.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our bylaws provide that, to the fullest extent permitted by law, unless we agree in writing to an alternative forum, (1) the Delaware Court of Chancery (or, if such court does not have, or declines to accept, jurisdiction, another state court or a
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
We expect to begin construction of one or more commercial-scale DPF facilities well before our xenotransplantation products could potentially be approved, and if If development of our xenotransplantation products fails or demand is significantly less than anticipated, we will not recoup our significant investment in these facilities. unique facilities as they would be difficult to repurpose.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is difficult to predict the impact, if any, that future legislation federal or state legislation, or executive actions actions, might have on the use of and reimbursement for our products in the United States, including such as the potential for the importation of generic versions of our products, for price caps under state laws, or for increased difficulties and costs related to the distribution of our products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
If successful, citizen Citizens petitions can have in the past, and may in the future, significantly delay, delay or even prevent, the prevent approval of our products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we do not directly source any raw materials or consumables from Ukraine, Russia, Belarus, Gaza, Lebanon, or Israel, the directly impacted countries, our European- and Middle East-based international suppliers and service providers in these regions could be impacted by extended conflicts or an escalation of these conflicts into neighboring countries.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
The regulatory approval process is particularly uncertain for our transplantation programs, which include the development of xenotransplantation, regenerative medicine, 3D bioprinting of organ alternatives, and cell-based products. manufacturing program.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Smiths Medical (which has since been acquired by ICU Medical) discontinued manufacturing the MS-3 system used to administer subcutaneous Remodulin, and specialty pharmacy distributors informed us that supplies of new MS-3 pumps are fully exhausted. exhausted, although a limited number of refurbished pumps may be available for use with generic treprostinil.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
These state legislative measures could limit the price or payment for certain drugs, and a A number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with state law requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information under transparency obligations.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We could be held liable for errors in our the submissions we are required to make with regards to governmental drug pricing data, program, including retroactive rebates and program refunds.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may incur significant civil monetary penalties if we are found to have knowingly provided false information to the government or to have charged 340B covered entities more than the statutorily mandated ceiling price. price, and resolution of any claims that we violated these provisions could be costly.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
(5) we, or clinical trial sites or other third parties, do not adhere to trial protocols and required quality controls under good clinical practices (GCP) regulations and similar regulations outside the United States; GCP regulations;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
We currently rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us. us, with no plans to develop an alternate or backup supply arrangement.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedRisk Factors
Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Medicare Part D coverage gap discount program with a new manufacturer discounting program (beginning in 2025).
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The approval and launch of new therapies may materially negatively impact sales of our current and potential new products.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Should the prices of raw materials and consumables further increase significantly as a result of inflation or tariffs, we could see higher than average year-over-year increases in cost of goods sold.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
The fair value of stock options is measured using inputs and assumptions under the Black-Scholes-Merton model. The fair value of restricted stock units is measured using our stock price on the date of grant.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
(1)Excluding impairment of PP&E and litigation accrual. See Impairment of PP&E and Litigation accrual sections below.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
Impairment of PP&E. During the second quarter of 2025, we recorded a $21.7 million impairment charge to write down the carrying value of certain PP&E.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
In March 2022, we entered into a credit agreement (the 2022 Credit Agreement) with Wells Fargo, as administrative agent and a swingline lender, and various other lender parties, which provided for: (1) an unsecured revolving credit facility of up to $1.2 billion; and (2) a second unsecured revolving credit facility of up to $800.0 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
(1)We have contractual obligations to pay unused commitment fees under the 2025 Credit Agreement. As of December 31, 2025, our outstanding balance on the 2025 Credit Agreement was zero.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
AddedMD&A
details. In addition, we may owe additional earn-out consideration to the former securityholders of IVIVA, as described in Note 15—Acquisitions—Asset Acquisition to our consolidated financial statements.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RemovedMD&A
•The anticipated impact our rebate agreements with pharmacy benefit managers will have on our net revenues;
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
The fair value of STAP awards and stock options is measured using inputs and assumptions under the Black-Scholes-Merton model. The fair value of restricted stock units is measured using our stock price on the date of grant. Although we no longer grant STAP awards, we had approximately 0.1 million STAP awards outstanding as of December 31, 2024. We account for STAP awards as liabilities because they are settled in cash. As such, we must re-measure the fair value of STAP awards at the end of each financial reporting period until the awards are no longer outstanding. Changes in our liability associated with outstanding STAP awards as a result of such re-measurements are recorded as adjustments to share-based compensation expense (benefit) and can create volatility within our operating expenses from period to period. The following factors, among others, impact the amount of share-based compensation expense (benefit) recognized in connection with STAP awards from period to period: (1) volatility in the price of our common stock (specifically, increases in the price of our common stock will generally result in an increase in our liability and related compensation expense, while decreases in our stock price will generally result in a reduction in our liability and related compensation expense); and (2) decreases in the number of outstanding awards.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
We have entered into contracts with all of the major pharmacy benefit managers for Part D and commercial insurance plans, which provide rebates on utilization of Tyvaso DPI and, in some cases, Orenitram and nebulized Tyvaso. We entered into these rebate agreements to encourage access to these therapies. Many of these rebates went into effect beginning in the second half of 2024, which impacted our net revenues by increasing gross-to-net deductions for the relevant products. These rebate contracts are effective at least through 2025.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1)Long-term debt obligations include future principal and interest payments on our adjusted variable rate obligations under the 2022 Credit Agreement. The 2022 Credit Agreement will mature in March 2029. As of December 31, 2024, we have classified the outstanding balance of $300.0 million as a current liability on our consolidated balance sheet, as we intend to repay this amount within one year. See Note 7—Debt to our consolidated financial statements for further details.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(2)Estimated based on the intrinsic value of exercisable outstanding STAP awards as of December 31, 2024. See Note 8—Share-Based Compensation—STAP Awards to our consolidated financial statements for further details.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
(2) (1) an increase in restricted stock unit expense due to a greater number of awards granted and remaining outstanding in 2024, performance-based restricted stock units during the year ended December 31, 2025, as compared to the same period in 2023; 2024; and (3) (2) an increase in stock option expense due to a greater number of awards granted in 2024, unvested and outstanding performance-based stock options during the year ended December 31, 2025, as compared to the same period in 2023. 2024, partially offset by a decrease in STAP expense, as all remaining STAP awards were exercised during the first quarter of 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, we recorded $40.2 million and $8.0 (a) $42.2 million in expense related to upfront non-refundable licensing milestone payments for drug delivery device technologies and ex vivo lung formulation technologies; and (b) $10.8 million in expense related to adjustments to the fair value of contingent consideration obligations for manufactured organ and organ alternative projects.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
(CVS Specialty) We have entered into separate, non-exclusive distribution agreements with Accredo and CVS Specialty to distribute Tyvaso DPI, nebulized Nebulized Tyvaso, Remodulin, the Remunity Pump, and RemunityPRO Pumps, and Orenitram in the United States, and we have entered into an exclusive distribution agreement with ASD Specialty Healthcare, Inc., an affiliate of Cencora, Inc. Cencora Global Procurement Ltd. to distribute Unituxin in the United States.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Liquidia’s patent lawsuit against the FDA us related to the FDA’s decision to grant us a period of exclusivity and our cross-claims against the FDA related to Liquidia’s efforts to add an indication for PH-ILD to the NDA for Yutrepia; Tyvaso DPI; and our litigation with Humana Inc., United Healthcare Services, Inc., MSP Recovery Claims, Series LLC, and related entities;
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Under the 2025 ASR agreement, agreements, we made an aggregate upfront payment of $1.0 billion to Citi and received an aggregate initial delivery deliveries of 3,275,199 1,274,296 and 849,531 shares of our common stock on March 27, 2024, which represented August 4, 2025, representing approximately 80 75 percent and 50 percent of the total shares that would be repurchased under the Uncollared ASR agreement, and Collared ASR, respectively, measured based on the closing price of our common stock on March 25, 2024. August 1, 2025.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
This amount is primarily dedicated to construction of a new Tyvaso DPI manufacturing facility in Research Triangle Park, North Carolina (RTP); RTP; and construction of a clinical-scale designated pathogen-free (DPF) facility DPF facilities in Stewartville, Minnesota; Minnesota and initial pre-construction activities for a commercial-scale DPF facility. Houston, Texas.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
On March 31, 2022, April 25, 2025, we borrowed $800.0 $200.0 million under the facilities 2025 Credit Agreement and used the funds proceeds to repay all outstanding indebtedness under our then-existing credit agreement. the 2022 Credit Agreement in connection with its termination.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Our The most significant rebates we pay include rebates that relate to our participation in state Medicaid programs, various government healthcare programs (including Medicare Part D inflationary rebates required under the IRA), contractual rebates to certain of our domestic distributors, and contractual rebates offered we pay to managed care organizations covering Medicare Part D and commercial plans.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
(1) a $1,099.7 $682.6 million decrease increase in cash used for total purchases, sales, and maturities of marketable investments; and (2) an $89.2 a $274.0 million decrease increase in net cash paid related to the acquisitions of IVIVA purchase property, plant, and Miromatrix in 2023; partially offset by: equipment.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Estimates associated with our participation in state Medicaid government healthcare programs are particularly susceptible to adjustment given the extensive time lag that may occur between our recording of an accrual and its ultimate invoicing by individual state Medicaid programs, which can occur up to several years after the sale of our product. invoicing.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Total Tyvaso net product sales grew 31 16 percent to $1,878.2 million in 2025, compared to $1,620.4 million in 2024, compared to $1,233.7 million for 2023. driven by growth in Tyvaso DPI net product sales.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new
RewordedMD&A
Tyvaso DPI net product sales increased in 2024, 2025, as compared to 2023, 2024, primarily due to an increase in quantities sold of $269.2 million and, to a lesser extent, price increases, partially offset by higher gross-to-net revenue deductions. $268.5 million.
Read it in 10-K Feb 25, 2026 at sec.govopen_in_new